Stock Analysis on Net
Stock Analysis on Net

Stryker Corp. (NYSE:SYK)

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Beginner level

Historical Valuation Ratios (Summary)

Stryker Corp., historical price multiples (quarterly data)

Microsoft Excel LibreOffice Calc
Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Price to earnings (P/E) 69.46 57.72 43.23 45.35 31.33 39.24 23.72 22.60 19.64 18.96 48.55 58.86 62.59 54.36 33.60 32.52 29.96 27.92
Price to operating profit (P/OP) 47.78 41.52 31.40 33.20 24.04 30.13 32.94 33.22 27.96 26.55 23.52 25.45 27.41 24.21 26.70 25.11 22.99 21.23
Price to sales (P/S) 6.65 6.43 5.34 5.16 4.53 5.49 5.59 5.65 4.98 4.95 4.52 4.88 5.01 4.46 4.93 4.62 4.29 4.06
Price to book value (P/BV) 7.24 7.05 5.85 5.69 5.17 6.38 6.60 6.72 5.92 5.74 6.09 6.72 6.92 5.56 5.73 5.51 5.21 4.82 4.59 4.81 4.65

Based on: 10-Q (filing date: 2021-04-28), 10-K (filing date: 2021-02-11), 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-30), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-22), 10-Q (filing date: 2016-04-22).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Stryker Corp.’s P/E ratio increased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Stryker Corp.’s P/OP ratio increased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Stryker Corp.’s P/S ratio increased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Stryker Corp.’s P/BV ratio increased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.

Price to Earnings (P/E)

Stryker Corp., historical P/E calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
No. shares of common stock outstanding1 376,747,866 376,200,942 375,790,657 375,605,813 375,378,477 374,575,145 374,366,776 374,103,607 373,810,085 372,664,636 374,187,286 373,990,494 373,710,934 374,642,060 374,237,631 374,063,294 373,765,028 372,878,298 374,451,718 374,302,065 373,981,097
Selected Financial Data (US$)
Net earnings (loss) (in millions) 302  568  621  (83) 493  725  466  480  412  2,068  590  452  443  (249) 434  391  444  510  355  380  402 
Earnings per share (EPS)2 3.74 4.25 4.67 4.26 5.76 5.56 9.15 9.49 9.42 9.53 3.30 2.89 2.73 2.72 4.75 4.54 4.52 4.42 0.00 0.00 0.00
Share price1, 3 259.58 245.34 202.01 193.30 180.62 218.24 217.09 214.45 185.04 180.75 160.38 169.98 170.67 148.01 159.74 147.80 135.37 123.32 114.27 117.03 109.40
Valuation Ratio
P/E ratio4 69.46 57.72 43.23 45.35 31.33 39.24 23.72 22.60 19.64 18.96 48.55 58.86 62.59 54.36 33.60 32.52 29.96 27.92
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 36.79 48.49 58.45 58.36 45.61 41.83 44.92 53.17 52.98 56.47 136.66 122.73 213.07 220.29 45.00 73.04 50.48 55.16
Anthem Inc. 19.99 15.87 14.35 11.97 14.80 15.96 15.55 18.14 16.19 21.45 15.64 14.84 14.70 15.44 17.72 17.04 17.09 17.48
Becton, Dickinson & Co. 49.11 86.01 95.62 75.45 90.00 65.09 83.38 66.87 72.88 408.36 105.60 206.04 49.63 59.56 30.05 28.94 36.65 32.09 43.18 41.64
Boston Scientific Corp. 304.26 13.68 13.56 11.72 11.86 51.90 42.77 28.42 33.06 73.07 89.21 363.19 354.70 44.70 46.56 83.30 96.19
Bristol-Myers Squibb Co. 144.77 41.99 16.53 11.97 14.51 16.81 56.09 251.38 92.56 103.55 23.59 19.40 18.96 20.56
CVS Health Corp. 14.44 12.88 10.69 10.20 10.94 14.15 20.65 17.46 25.50 23.08 10.05 10.69 13.42 15.08 15.71 14.91
Danaher Corp. 39.26 44.49 46.61 41.91 35.88 38.34 40.31 41.93 37.63 29.77 25.70 27.06 27.78 27.25 26.31 26.25 25.00 23.02
Edwards Lifesciences Corp. 70.70 66.48 61.28 65.79 39.74 46.05 61.52 61.07 47.99 51.14 41.12 45.24 48.67 48.16 28.95 34.05 35.04 33.48
Intuitive Surgical Inc. 89.95 87.47 82.17 70.73 44.28 48.72 49.80 51.02 53.16 53.03 73.32 73.33 69.50 70.95 45.87 42.21 38.18 37.16
Medtronic PLC 32.34 26.30 25.38 31.86 32.75 28.78 25.11 57.38 41.16 37.80 37.82 21.55 26.35 29.96 28.24 23.20 32.64 33.17
UnitedHealth Group Inc. 23.06 20.54 17.70 16.88 19.91 20.48 17.79 17.98 17.93 21.09 21.18 20.91 20.02 20.77 23.90 23.24 22.18 21.73

Based on: 10-Q (filing date: 2021-04-28), 10-K (filing date: 2021-02-11), 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-30), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-22), 10-Q (filing date: 2016-04-22).

1 Data adjusted for splits and stock dividends.

2 Q1 2021 Calculation
EPS = (Net earnings (loss)Q1 2021 + Net earnings (loss)Q4 2020 + Net earnings (loss)Q3 2020 + Net earnings (loss)Q2 2020) ÷ No. shares of common stock outstanding
= (302,000,000 + 568,000,000 + 621,000,000 + -83,000,000) ÷ 376,747,866 = 3.74

3 Closing price as at the filing date of Stryker Corp.’s Quarterly or Annual Report.

4 Q1 2021 Calculation
P/E ratio = Share price ÷ EPS
= 259.58 ÷ 3.74 = 69.46

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Stryker Corp.’s P/E ratio increased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.

Price to Operating Profit (P/OP)

Stryker Corp., historical P/OP calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
No. shares of common stock outstanding1 376,747,866 376,200,942 375,790,657 375,605,813 375,378,477 374,575,145 374,366,776 374,103,607 373,810,085 372,664,636 374,187,286 373,990,494 373,710,934 374,642,060 374,237,631 374,063,294 373,765,028 372,878,298 374,451,718 374,302,065 373,981,097
Selected Financial Data (US$)
Operating income (loss) (in millions) 459  749  859  (20) 635  944  628  613  528  698  576  672  591  712  523  501  554  661  486  500  519 
Operating profit per share2 5.43 5.91 6.43 5.82 7.51 7.24 6.59 6.46 6.62 6.81 6.82 6.68 6.23 6.11 5.98 5.89 5.89 5.81 0.00 0.00 0.00
Share price1, 3 259.58 245.34 202.01 193.30 180.62 218.24 217.09 214.45 185.04 180.75 160.38 169.98 170.67 148.01 159.74 147.80 135.37 123.32 114.27 117.03 109.40
Valuation Ratio
P/OP ratio4 47.78 41.52 31.40 33.20 24.04 30.13 32.94 33.22 27.96 26.55 23.52 25.45 27.41 24.21 26.70 25.11 22.99 21.23
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 31.39 40.69 45.82 45.19 35.87 34.03 34.32 37.50 36.74 36.64 38.12 38.00 39.99 60.88 47.72 41.32 30.85 24.25
Anthem Inc. 15.79 12.10 10.93 9.03 11.95 13.55 12.60 14.74 12.58 15.87 15.01 14.22 14.34 14.81 12.35 11.12 10.24 9.36
Becton, Dickinson & Co. 33.30 44.46 56.20 43.34 49.82 40.02 29.43 29.40 30.27 43.37 47.87 95.72 67.53 34.59 40.06 21.15 20.05 25.02 22.42 27.98 26.60
Boston Scientific Corp. 424.69 630.22 80.81 44.72 36.71 34.77 36.58 31.15 36.68 32.51 31.09 30.63 28.71 34.07 34.07 69.95 74.67
Bristol-Myers Squibb Co. 39.45 33.97 27.33 24.42 13.51 10.89 13.68 16.16 19.56 27.48 23.10 28.87 24.60 20.23 19.09 19.79
CVS Health Corp. 7.61 6.65 5.89 5.98 6.19 7.83 9.44 8.02 15.80 18.65 12.59 11.14 6.90 7.44 7.19 8.21 8.07 7.65
Danaher Corp. 32.62 36.91 46.28 43.09 35.22 34.47 29.97 30.85 26.85 23.18 20.95 21.72 22.58 22.48 22.35 21.13 20.83 21.37
Edwards Lifesciences Corp. 65.18 60.98 56.78 61.66 35.77 42.04 57.30 56.37 47.70 49.37 26.74 28.00 25.96 25.66 22.59 26.24 26.76 25.38
Intuitive Surgical Inc. 89.18 88.37 83.88 71.30 43.68 48.89 50.00 49.12 51.89 49.87 48.90 50.69 46.82 44.40 41.74 35.53 31.07 28.93
Medtronic PLC 35.86 26.29 21.01 23.52 22.21 21.26 19.74 21.13 20.04 17.64 16.73 17.82 19.53 22.64 21.53 18.18 22.35 22.18
UnitedHealth Group Inc. 16.12 14.12 12.35 11.85 13.80 14.40 12.43 12.51 12.48 14.58 15.82 15.19 14.17 14.42 14.30 13.54 12.56 11.79

Based on: 10-Q (filing date: 2021-04-28), 10-K (filing date: 2021-02-11), 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-30), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-22), 10-Q (filing date: 2016-04-22).

1 Data adjusted for splits and stock dividends.

2 Q1 2021 Calculation
Operating profit per share = (Operating income (loss)Q1 2021 + Operating income (loss)Q4 2020 + Operating income (loss)Q3 2020 + Operating income (loss)Q2 2020) ÷ No. shares of common stock outstanding
= (459,000,000 + 749,000,000 + 859,000,000 + -20,000,000) ÷ 376,747,866 = 5.43

3 Closing price as at the filing date of Stryker Corp.’s Quarterly or Annual Report.

4 Q1 2021 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 259.58 ÷ 5.43 = 47.78

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Stryker Corp.’s P/OP ratio increased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.

Price to Sales (P/S)

Stryker Corp., historical P/S calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
No. shares of common stock outstanding1 376,747,866 376,200,942 375,790,657 375,605,813 375,378,477 374,575,145 374,366,776 374,103,607 373,810,085 372,664,636 374,187,286 373,990,494 373,710,934 374,642,060 374,237,631 374,063,294 373,765,028 372,878,298 374,451,718 374,302,065 373,981,097
Selected Financial Data (US$)
Net sales (in millions) 3,953  4,262  3,737  2,764  3,588  4,131  3,587  3,650  3,516  3,796  3,242  3,322  3,241  3,471  3,006  3,012  2,955  3,157  2,833  2,840  2,495 
Sales per share2 39.06 38.15 37.84 37.46 39.84 39.74 38.86 37.97 37.12 36.50 35.48 34.87 34.06 33.22 32.41 31.97 31.53 30.37 0.00 0.00 0.00
Share price1, 3 259.58 245.34 202.01 193.30 180.62 218.24 217.09 214.45 185.04 180.75 160.38 169.98 170.67 148.01 159.74 147.80 135.37 123.32 114.27 117.03 109.40
Valuation Ratio
P/S ratio4 6.65 6.43 5.34 5.16 4.53 5.49 5.59 5.65 4.98 4.95 4.52 4.88 5.01 4.46 4.93 4.62 4.29 4.06
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 5.64 6.30 6.13 5.77 5.09 4.83 4.72 4.98 4.52 4.37 3.98 3.84 3.57 3.84 3.77 3.62 3.40 3.70
Anthem Inc. 0.76 0.60 0.61 0.63 0.65 0.74 0.67 0.77 0.69 0.88 0.79 0.72 0.68 0.67 0.60 0.56 0.55 0.51
Becton, Dickinson & Co. 4.07 3.85 4.45 4.00 3.94 4.07 3.82 3.64 3.82 4.06 4.45 4.49 4.94 4.23 3.72 3.21 3.05 2.87 2.97 2.86 2.55
Boston Scientific Corp. 6.04 5.54 4.99 5.31 4.66 5.19 5.44 5.92 5.14 5.62 5.06 4.89 4.39 4.08 4.27 4.21 4.22 3.98
Bristol-Myers Squibb Co. 3.28 3.16 3.66 3.97 4.45 5.52 3.87 3.11 3.21 3.67 3.64 4.38 4.04 5.02 4.85 4.40 4.59 4.72
CVS Health Corp. 0.40 0.35 0.32 0.32 0.30 0.37 0.38 0.33 0.36 0.39 0.42 0.37 0.36 0.38 0.37 0.44 0.45 0.45
Danaher Corp. 7.27 7.01 8.15 7.48 6.34 6.29 5.32 5.43 4.67 3.97 3.62 3.74 3.77 3.70 3.52 3.32 3.35 3.48
Edwards Lifesciences Corp. 13.45 12.48 11.14 11.32 9.82 11.09 11.46 11.17 9.61 9.92 8.06 8.37 7.91 8.18 6.51 7.55 7.31 6.43
Intuitive Surgical Inc. 23.19 21.29 20.09 18.44 13.33 15.01 15.41 15.28 15.83 16.06 16.36 17.01 16.16 14.96 13.83 12.01 10.69 10.11
Medtronic PLC 5.11 4.36 4.34 4.82 4.72 4.36 4.04 4.27 4.35 3.92 3.57 3.65 3.62 4.06 3.82 3.39 4.14 4.07
UnitedHealth Group Inc. 1.49 1.24 1.18 1.17 1.12 1.18 1.00 1.00 0.98 1.12 1.22 1.17 1.09 1.10 1.05 0.98 0.89 0.83

Based on: 10-Q (filing date: 2021-04-28), 10-K (filing date: 2021-02-11), 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-30), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-22), 10-Q (filing date: 2016-04-22).

1 Data adjusted for splits and stock dividends.

2 Q1 2021 Calculation
Sales per share = (Net salesQ1 2021 + Net salesQ4 2020 + Net salesQ3 2020 + Net salesQ2 2020) ÷ No. shares of common stock outstanding
= (3,953,000,000 + 4,262,000,000 + 3,737,000,000 + 2,764,000,000) ÷ 376,747,866 = 39.06

3 Closing price as at the filing date of Stryker Corp.’s Quarterly or Annual Report.

4 Q1 2021 Calculation
P/S ratio = Share price ÷ Sales per share
= 259.58 ÷ 39.06 = 6.65

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Stryker Corp.’s P/S ratio increased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.

Price to Book Value (P/BV)

Stryker Corp., historical P/BV calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
No. shares of common stock outstanding1 376,747,866 376,200,942 375,790,657 375,605,813 375,378,477 374,575,145 374,366,776 374,103,607 373,810,085 372,664,636 374,187,286 373,990,494 373,710,934 374,642,060 374,237,631 374,063,294 373,765,028 372,878,298 374,451,718 374,302,065 373,981,097
Selected Financial Data (US$)
Total Stryker shareholders’ equity (in millions) 13,502  13,084  12,986  12,754  13,115  12,807  12,315  11,943  11,693  11,730  9,860  9,460  9,214  9,966  10,425  10,035  9,704  9,550  9,332  9,098  8,808 
Book value per share (BVPS)2 35.84 34.78 34.56 33.96 34.94 34.19 32.90 31.92 31.28 31.48 26.35 25.29 24.66 26.60 27.86 26.83 25.96 25.61 24.92 24.31 23.55
Share price1, 3 259.58 245.34 202.01 193.30 180.62 218.24 217.09 214.45 185.04 180.75 160.38 169.98 170.67 148.01 159.74 147.80 135.37 123.32 114.27 117.03 109.40
Valuation Ratio
P/BV ratio4 7.24 7.05 5.85 5.69 5.17 6.38 6.60 6.72 5.92 5.74 6.09 6.72 6.92 5.56 5.73 5.51 5.21 4.82 4.59 4.81 4.65
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 6.27 6.65 6.30 5.94 5.40 4.96 4.65 4.86 4.49 4.38 3.94 3.72 3.23 3.40 2.95 2.71 2.42 3.76 2.72 3.20 2.70
Anthem Inc. 2.78 2.19 2.10 2.06 2.23 2.42 2.13 2.40 2.15 2.82 2.45 2.24 2.26 2.24 2.04 1.84 1.82 1.72 1.31 1.45 1.62
Becton, Dickinson & Co. 3.00 2.78 3.13 3.32 3.23 3.34 3.04 2.91 3.05 3.09 3.07 2.87 2.85 3.95 3.60 4.96 4.99 4.69 4.55 4.56 3.97
Boston Scientific Corp. 3.89 3.58 3.24 3.46 3.64 4.02 5.83 6.33 5.53 6.33 5.91 6.00 5.79 5.26 4.97 5.07 5.14 4.96 4.52 5.22 4.58
Bristol-Myers Squibb Co. 3.73 3.55 2.87 2.82 2.77 2.80 5.30 4.63 4.91 5.89 5.89 7.67 6.65 8.88 6.75 6.05 6.36 5.66 5.56 8.36 8.38
CVS Health Corp. 1.51 1.33 1.24 1.24 1.21 1.47 1.47 1.23 1.25 1.29 2.17 1.95 1.73 1.88 1.94 2.34 2.38 2.15 2.18 3.01 3.10
Danaher Corp. 4.46 3.93 4.38 3.90 3.68 3.72 3.02 3.19 2.88 2.80 2.56 2.65 2.61 2.58 2.47 2.35 2.42 2.56 2.39 2.24 2.70
Edwards Lifesciences Corp. 12.91 11.97 11.56 12.74 11.29 11.62 12.48 12.65 10.65 11.76 8.72 9.39 8.40 9.51 6.82 8.30 8.39 7.28 7.64 9.86 9.78
Intuitive Surgical Inc. 10.40 9.53 9.35 9.19 7.22 8.13 8.43 8.49 8.68 8.96 9.30 10.03 9.71 9.91 8.35 7.62 7.21 4.73 4.77 5.22 5.00
Medtronic PLC 2.84 2.48 2.60 2.94 2.87 2.66 2.48 2.62 2.59 2.31 2.11 2.10 2.14 2.40 2.27 1.96 2.34 2.25 2.08 2.09 1.86
UnitedHealth Group Inc. 5.86 4.83 4.54 4.53 4.81 4.92 4.32 4.40 4.37 4.89 5.32 5.13 4.72 4.59 4.55 4.37 4.01 3.98 3.61 3.75 3.57

Based on: 10-Q (filing date: 2021-04-28), 10-K (filing date: 2021-02-11), 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-30), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-22), 10-Q (filing date: 2016-04-22).

1 Data adjusted for splits and stock dividends.

2 Q1 2021 Calculation
BVPS = Total Stryker shareholders’ equity ÷ No. shares of common stock outstanding
= 13,502,000,000 ÷ 376,747,866 = 35.84

3 Closing price as at the filing date of Stryker Corp.’s Quarterly or Annual Report.

4 Q1 2021 Calculation
P/BV ratio = Share price ÷ BVPS
= 259.58 ÷ 35.84 = 7.24

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Stryker Corp.’s P/BV ratio increased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.